Lung cancer prognosis in Spain: The role of histology, age and sex  by Salmerón, D. et al.
Respiratory Medicine (2012) 106, 1301e1308Available online at www.sciencedirect.com
journal homepage: www.elsevier .com/locate/rmedLung cancer prognosis in Spain: The role
of histology, age and sexD. Salmero´n a,b,i, M.D. Chirlaque a,b,*, M. Isabel Izarzugaza c,
M.J. Sa´nchez b,d, R. Marcos-Gragera b,e, E. Ardanaz b,f, J. Galceran g,
A. Mateos h, C. Navarro a,b,iaMurcia Cancer Registry, Department of Epidemiology, Regional Health Authority, Murcia, Spain
bConsortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiologı´a y Salud Pu´blica e CIBERESP),
Spain
cBasque Country Cancer Registry, Basque Country Regional Authority, Vitoria-Gasteiz, Spain
dGranada Cancer Registry, Andalusian School of Public Health, Granada, Spain
eGirona Epidemiology Unit and Cancer Registry, Oncology Planning, Department of Health, Girona, Spain
fNavarre Cancer Registry, Navarre Public Health Institute, Pamplona, Spain
gTarragona Cancer Registry, Foundation Society for Cancer Research & Prevention, IISPV, Reus, Spain
hAlbacete Cancer Registry, Health and Social Welfare Authority, Castile-La Mancha, Spain
iDepartment of Social & Health Sciences, University of Murcia School of Medicine, Spain
Received 28 September 2011; accepted 4 June 2012
Available online 29 June 2012KEYWORDS
Cancer;
Lung cancer survival;
Histologic type;
Prognosis;
Population-based
cancer registries* Corresponding author. Consejerı´a
11, 30008 Murcia, Spain. Tel.: þ34 9
E-mail address: mdolores.chirlaqu
0954-6111/$ - see front matter ª 201
http://dx.doi.org/10.1016/j.rmed.201Summary
Survival in the case of lung cancer patients not only remains poor and decreases with
advancing age at diagnosis, but recent European studies also report that it differs by sex.
Our study sought to describe sex-related differences in lung cancer survival in Spain, and eval-
uate the role played by histologic type. Our analysis covered seven Spanish regions
with population-based cancer registries. Cases diagnosed with lung cancer during the period
1995e1999 were followed up until December 31, 2004. To ascertain possible sex differences
we performed multiple regression analysis. Age-standardized 5-year relative survival proved
significantly higher in women (11.8%) than in men (9.2%), and among the youngest patients
relative survival at 5 years conditional on surviving 1 year, was 1.74 times significantly higher
in women than in men. The regression analysis showed that men had a higher relative excess
risk of dying (RER) than did women (1.1 [95% CI 1.03e1.18]), with this being particularly
marked among the 15e54 age group (1.42 [1.24e1.64]). Analysis by histologic type showed
that in small cell carcinoma, men had a higher RER than women (1.29 [1.02e1.61]); inde Sanidad y Polı´tica Social de la Regio´n de Murcia, Servicio de Epidemiologı´a, Ronda de Levante
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1302 D. Salmero´n et al.squamous cell carcinoma, men had a significantly lower RER than women during the first and
fifth years; and in large cell carcinoma and adenocarcinoma, the RER displayed no significant
sex-related differences.
Lung cancer survival rates in Spain are poor, with better prognosis in women, especially
among patients aged under 55 years at diagnosis, or those with small cell carcinoma.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
In Europe, lung cancer mortality is declining in men and
rising in women,1 with cigarette smoking being the major
risk factors. Lung cancer appears to have a better prognosis
in women than in men.2,3 Recently, sex-related differences
for 26 cancer sites were reported in Europe,4 with relative
survival in lung cancer being higher in women than in men.
In the USA too, women with lung cancer have been
reported as displaying better survival,5 suggesting that the
natural history of lung cancer may differ in women and
men, and that one factor which may account for women’s
advantages is that the distribution of cancer morphologies
with differing prognoses varies between men and women.
Regardless of histologic type, however, some studies
suggest that this sex-related difference remains present in
cancer survival, with better prognosis among women.
Among the possible reasons for these differences currently
under discussion, reference has been made to hormonal
factors.6e8 Whether estrogen and progestron play a role in
the favorable progression of lung cancer in women is
unknown but several studies have addressed this issue with
inconclusive results.
In Spain, while population-based survival rates for lung
cancer broken down by sex and age group have previously
been published,9e11 no study has yet targeted sex-related
differences by morphological group. Accordingly, our
study sought to do this, by analyzing Spanish survival data in
order to furnish sex-related differences in relative survival,
stratified by histologic type.
Patients and methods
This study targeted seven Spanish regions covered by
population-based cancer registries, which had been oper-
ating successfully for over 15 years and were located in the
north (Basque Country and Navarre), north-east (Girona
and Tarragona) and south (Albacete, Murcia and Granada)
of the country, representing 15% of the total Spanish pop-
ulation. These registries regularly publish their data in
Cancer Incidence in Five Continents (CIFC) monographs,12
in which they have obtained good global quality indica-
tors13 with high coverage for the period 1998e2002, are
members of the European Network of Cancer Registries,14
and collaborate in the EUROCARE study.9
Cases diagnosed with lung cancer during the period
1995e1999 were followed up until December 31, 2004. All
the registries conducted follow-up procedures so as to
obtain the most accurate information on vital status, using
the National Death Index (NDI)15,16 and common criteria at
all centers. More specifically, if a case was not found in theNDI, “alive” vital status was not allocated: instead, other
sources, such as the social security database (which belongs
to the National Health Service), hospital clinical records,
primary-care records, and municipal electoral rolls were
used where available. Data-quality was verified using both
the IARC-check17 and EUROCARE rules.18
Patients aged 15 years and over were included in the
analysis, and the third version of International Classifica-
tion of Diseases for Oncology (ICDO-3)19 was used to code
topography and morphology. The characteristics of the lung
cancer cases (ICD-10 C33e34) diagnosed in the period
1995e1999 and included in the analysis have been
described elsewhere.11 In brief, the dataset from the
Spanish cancer registries that participated in this study
comprised a total of 13,193 incident lung cancer cases. If
a malignant tumor was not the first cancer in a given
patient (6.0%), or the death certificate was the only infor-
mation available to register the case (4.7%), or the cancer
was diagnosed at autopsy (0.3%), then the tumor was
excluded form the analysis in accordance with standard
procedures.18 After excluding these cases there were
11,809 cases for survival analysis. From these, patients
whose survival time was zero (6.9%) have not been
considered for the analysis as these patients are not at
risk.20,21 The morphology codes were grouped22 into the
following 5 categories: small cell lung carcinoma (ICDO-3
codes 8041e8045); large cell lung carcinoma (8012e8021,
8031, 8310); squamous cell lung carcinoma (8050e8082);
adenocarcinoma (8140e8191, 8201e8221, 8250e8300,
8312e8420, 8440e8550) and other/unspecified (within this
category almost 90% of cases were malignant neoplasms
and carcinomas not otherwise specified).Statistical methods
The STREL survival analysis algorithm (Cancer Research UK
Survival Group (2006), version 6. Non-Communicable
Disease Epidemiology Unit, London School of Hygiene and
Tropical Medicine, UK) implemented in STATA software23
and based on the maximum likelihood method applied to
individual records,24 was used to estimate relative survival
(RS) and 95% confidence intervals.
Relative survival was calculated by sex, age group and
histologic type. Survival estimates were adjusted using the
international standard for cancer survival analysis/ICSS.25
The present paper also analyses five-year relative survival
conditional to surviving the first year after diagnosis.9 A
proportion of patients with advanced stage die during the
first year, and those who survive have a more uniform stage
distribution. Also comorbidities, particularly in older
patients, mainly increase mortality during the year
Lung cancer prognosis in Spain 1303following diagnosis. These two factors are again partly
dependent on the quality of health care and therefore
conditional five-year survival reflects the care process and
the presence of comorbidities.26 Relative survival at five
years since diagnosis conditional to surviving one year was
calculated as the ratio of cumulative relative survival at
five years to relative survival at one year.
In order to furnish sex-related differences, we per-
formed a multiple regression analysis within the framework
of generalized linear models, using a Poisson assumption for
the observed number of deaths based on collapsed data,27
and the STATA computer software program.23 This analysis
took the following into account: follow-up duration; sex;
age at diagnosis (15e54, 55e64, 65þ years); and region
(three categories, i.e., north, north-east and south). For all
histologic types combined, the regression was additionally
stratified by age group. For each histologic type, the
regression took the following into account: follow-up
duration; sex; age at diagnosis (15e54, 55e64, 65þ
years); and region (two categories, with north and north-
east grouped together as the first). Interactions were
evaluated using the likelihood ratio test. The models esti-
mated the relative excess risk of dying (RER) vis-a`-vis the
respective reference category.
Results
A total of 10,999 population-based lung cancer cases (10.3%
female) were included in the analysis. Median age at
diagnosis was 67 years across the sexes. Women accountedTable 1 Distribution of the lung cancer cases considered in the
type. Number and percentage of cases.
Male
n %
Age group (years)
15e44 427 4.3
45e54 1233 12.5
55e64 2391 24.2
65e74 3724 37.7
75e99 2094 21.2
Registry
Albacete 506 5.1
Basque Country 3657 37.1
Girona 1047 10.6
Granada 1177 11.9
Murcia 1616 16.4
Navarre 934 9.5
Tarragona 932 9.4
Histologic type
Small cell
carcinoma
1668 16.9
Large cell
carcinoma
807 8.2
Squamous cell
carcinoma
3905 39.6
Adenocarcinoma 1673 17
Other/unspecified 1816 18.4for 20.5% of all patients aged under 50 years, and for 22.4%
of older patients (ages 85e99 years).
The distribution of the lung cancer cases by sex, age
group, registry and histologic type is shown in Table 1. Nearly
half the patients were diagnosed in the north, and practi-
cally a third in the south. Adenocarcinoma accounted for
approximately half of all lung cancer cases in women, with
small and large cell carcinoma being the least frequent.
Among men, approximately 4 in 10 cases were diagnosed
with squamous cell carcinoma (the most frequent), and 1 in
12 with large cell carcinoma. In the category other/
unspecified the percentage of cases not microscopically
verified (MV) was 57% in men and 43% in women; for other
specified morphologies the percentage of carcinoid tumors
(ICD-O 824) was 19% in females and 4% in males.
For all histologic types combined, age-standardized 5-
year relative survival was higher in women (11.8
[9.9e13.7]) than in men (9.2 [8.6e9.8]), due mainly to the
survival of patients under the age of 55 years (Fig. 1).
Relative survival at 5 years conditional to surviving 1 year
(RSC) showed a higher difference between males and
females for all ages except the 55e64 age group (Table 2).
For the youngest patients (ages 15e44 years), RSC among
women was 1.74 times higher than among men. The
regression analysis showed that men had a significantly
higher relative excess risk of dying (RER) than did women
(Table 3). Interactions between age and follow-up time (p-
value <0.05), and between age and sex (p-value <0.00005)
were statistically significant. When a separate analysis was
conducted for each age group, men had a significantlyanalyses, by sex, age group, cancer registry, and histologic
Female Total
n % n %
165 14.6 592 5.4
159 14.1 1392 12.7
190 16.8 2581 23.5
320 28.3 4044 36.8
296 26.2 2390 21.7
39 3.5 545 5
517 45.8 4174 37.9
106 9.4 1153 10.5
101 8.9 1278 11.6
164 14.5 1780 16.2
111 9.8 1045 9.5
92 8.1 1024 9.3
92 8.1 1760 16
89 7.9 896 8.1
146 12.9 4051 36.8
534 47.3 2207 20.1
269 23.8 2085 19
Figure 1 Relative survival (%) up to 5 years after diagnosis by sex and age group. All histologic type combined.
1304 D. Salmero´n et al.higher RER than did women among patients aged 15e54
years. Adjusting for follow-up duration, age at diagnosis,
region, and histologic type, men had a 14% excess risk of
dying with respect to women (1.14 [1.06e1.22]).
The breakdown by histologic type showed that 5-year
relative survival for small cell carcinoma and the other/
unspecified category was three times higher in women than
in men (Table 4). Men diagnosed with large cell carcinoma
displayed higher relative survival than did women (non-
significant). Among patients with squamous cell carcinoma
or adenocarcinoma, however, relative survival was higher
in women than in men (as from the second year in the case
of squamous cell carcinoma) but did not prove significant.Table 2 Relative survival at 5 years conditional on surviving 1
histologic types combined.
Male Femal
CRS 95% CI CRS
Age group
(years)
15e44 34.1 27.6e42.1 59.4
45e54 31.5 27.7e35.9 38.5
55e64 30.8 27.9e34.0 25.5
65e74 25.6 23.0e28.4 31.1
75e99 20.3 16.2e25.4 26.0
All 28.2 26.6e29.9 37.4
CRS, relative survival at 5 years conditional on surviving 1 year; andBased on the regression analysis (Table 5), men had
a higher RER than did women in the case of small cell carci-
noma and the other/unspecified category. No significant sex-
related differenceswere observed for patientswith large cell
carcinoma or adenocarcinoma. In the analysis of squamous
cell carcinoma, the interaction between sex and follow-up
time proved statistically significant, with men having
a significantly lower RER than women during the first (0.79
[0.64e0.97]) and fifth (0.29 [0.10e0.84]) years. The sex-and-
age interaction was not statistically significant (p-value>0.8)
in the analysis of small cell carcinomas. Analysis of the other/
unspecified category showed that the age-and-sex and age-
and-region interactions were statistically significant (p-year and 95% confidence interval, by age group and sex. All
e Total
95% CI CRS 95% CI
50.1e70.3 43.2 37.6e49.7
28.7e51.7 32.4 28.7e36.5
17.0e38.3 30.3 27.5e33.4
23.5e41.2 26.1 23.6e28.7
15.9e42.5 21.1 17.2e25.8
32.8e42.6 29.2 27.7e30.9
95% CI, 95% confidence interval.
Table 3 Relative excess risk of death and 95% confidence interval by age group. All histologic types combined.
Total 15e54 years 55e64 years 65e99 years
RER 95% CI RER 95% CI RER 95% CI RER 95% CI
FU
1 year 1 1 1 1
2 years 0.62 0.59e0.66 0.69 0.61e0.78 0.68 0.61e0.76 0.58 0.54e0.63
3 years 0.30 0.27e0.33 0.34 0.28e0.41 0.35 0.29e0.41 0.27 0.23e0.31
4 years 0.17 0.14e0.19 0.16 0.11e0.21 0.19 0.14e0.24 0.16 0.13e0.20
5 years 0.12 0.10e0.14 0.10 0.07e0.16 0.11 0.07e0.16 0.13 0.10e0.17
Sex
Female 1 1 1 1
Male 1.10 1.03e1.18 1.42 1.24e1.64 0.93 0.79e1.09 1.02 0.93e1.12
Region
North-east 1 1 1 1
North 0.89 0.85e0.94 0.84 0.74e0.96 0.92 0.82e1.04 0.90 0.84e0.96
South 1.05 0.99e1.11 0.94 0.81e1.08 1.01 0.89e1.13 1.10 1.02e1.18
Age group (years)
15e54 1
55e64 1.08 1.01e1.15
65e99 1.40 1.32e1.48
Deviance/df 1.36 0.98 1.04 0.90
df 76 19 21 22
FU, follow-up duration; RER, relative excess risk of death; 95% CI, 95% confidence interval; and df, degrees of freedom.
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men had a higher RER than women: 4.00 [2.41e6.63] in the
15e54 age group, 1.28 [0.84e1.93] in the 55e64 age group,
and 1.14 [0.96e1.35] among patients aged 65e99 years.
Discussion
This population-based study analyzed the relative survival
among lung cancer patients diagnosed in selected areas of
Spain over the period 1995e1999 and followed-up until
2004. Women displayed better survival than did men,
particularly among patients aged under 55 years. As against
women patients, men had a significantly higher RER for
small cell carcinoma, and a significantly lower RER during
the first (0.79 [0.64e0.97]) and fifth (0.29 [0.10e0.84])
years for squamous cell carcinoma. The south of Spain
registered a higher RER than the north for non-small cell
carcinoma. After adjusting for follow-up duration, age at
diagnosis, region, and histologic type, men had a 14%
excess risk of dying with respect to women (1.14
[1.06e1.22]). Among the youngest patients, relative
survival at 5 years conditional to surviving 1 year was 1.74
times significantly higher in women than in men, which
could reflect the more adequate care pattern in women and
the lower comorbidity.
Women’s marked improvement in survival among
patients under 55 years of age could be partly explained
by the advantage that conferred hormonal status in
premenopauseal women.4 Besides, exogenous hormone
treatment (postmenopauseal hormone-replacement
therapy) may increase the risk of dying from lung cancer,28
although in Spain, the prevalence of women users ofhormone-replacement therapy is low.29,30 The findings of
other studies indicate that estrogen exposure could even
confer a protective effect in lung cancer and a better
prognosis7 but in other study conclude that hormonal factors
would not explain the better survival of females.6
Although the hormonal role in lung cancer survival
among men is not clear, one theory put forward to explain
the general disadvantage faced by males in survival is that
androgens may have a stimulating effect on the growth of
lung cancer.8 This hypothesis would be in line with the
results observed by us for small cell carcinoma but not for
the other morphologic groups.
The high survival observed for women in the ‘other/
unspecified’ category could be partly explained by the
higher number of cases without MV in men resulting in
a lower survival due to the possibility of confounder among
metastasis and primary tumor. Another difference that
could help in the interpretation of the better survival in
women was the higher number of less aggressive tumor.
A different utilization of health-care services and
a different perception of health status by gender could also
play a role in the differences observed between male and
female in lung cancer prognosis. Several studies31,32
showed a worse health status perception by women and
thus have a greater need for health care making a more
frequent use of health services.
The age-adjusted relative survival figures estimated by
our study are close to those detected in Europe,4 where
women under the age of 65 years registered significantly
higher survival rates than did men.
Some differences have been observed across time in the
association between tobacco smoke and histologic type of
Table 4 Relative survival and 95% confidence interval, by sex and histologic type.
FU Male Female Total
RS 95% CI RS 95% CI RS 95% CI
1 year Small cell carcinoma 32.3 30.2e34.5 44.2 34.3e53.7 33.0 30.9e35.1
Large cell carcinoma 29.3 26.3e32.3 27.6 19.2e36.6 29.1 26.3e32.0
Squamous cell carcinoma 42.0 40.5e43.6 34.6 27.3e42.1 41.8 40.2e43.3
Adenocarcinoma 35.8 33.6e38.1 41.5 37.4e45.6 37.2 35.2e39.2
Other/unspecified 20.3 18.6e22.1 33.1 27.4e38.8 21.9 20.2e23.6
2 years Small cell carcinoma 9.5 8.2e11.0 17.6 10.5e26.1 9.9 8.6e11.4
Large cell carcinoma 13.9 11.6e16.3 11.7 6.2e19.1 13.6 11.5e16.0
Squamous cell carcinoma 23.3 22.0e24.7 25.1 18.5e32.3 23.4 22.0e24.7
Adenocarcinoma 21.6 19.6e23.6 23.8 20.2e27.5 22.1 20.4e23.9
Other/unspecified 10.5 9.2e11.9 26.0 20.8e31.5 12.4 11.0e13.8
3 years Small cell carcinoma 5.7 4.7e7.0 14.3 8.0e22.4 6.2 5.1e7.4
Large cell carcinoma 9.8 7.8e12.0 5.8 2.2e12.2 9.4 7.5e11.4
Squamous cell carcinoma 17.2 15.9e18.4 17.7 12.0e24.4 17.2 16.0e18.4
Adenocarcinoma 15.8 14.1e17.7 17.0 13.8e20.3 16.1 14.6e17.7
Other/unspecified 8.6 7.3e9.9 24.8 19.6e30.2 10.6 9.3e12.0
4 years Small cell carcinoma 4.8 3.8e5.9 13.8 7.5e22.0 5.3 4.3e6.4
Large cell carcinoma 7.8 6.0e9.9 4.8 1.6e11.0 7.5 5.8e9.4
Squamous cell carcinoma 14.6 13.5e15.8 16.2 10.7e22.8 14.7 13.6e15.9
Adenocarcinoma 13.0 11.4e14.8 14.0 11.1e17.2 13.3 11.8e14.8
Other/unspecified 7.4 6.2e8.6 22.8 17.8e28.2 9.3 8.1e10.6
5 year Small cell carcinoma 4.0 3.1e5.1 12.6 6.6e20.6 4.5 3.5e5.5
Large cell carcinoma 7.4 5.6e9.4 - 7.1 5.5e9.1
Squamous cell carcinoma 13.1 12.0e14.3 13.3 8.3e19.6 13.1 12.0e14.3
Adenocarcinoma 11.4 9.8e13.1 12.2 9.5e15.2 11.6 10.2e13.0
Other/unspecified 6.8 5.7e8.1 22.0 17.0e27.5 8.7 7.5e10.0
FU, follow-up duration; and 95% CI, 95% confidence interval.
The value for large cell carcinoma could not be calculated due to the low number of cases in women.
1306 D. Salmero´n et al.lung cancer.33 In the smoking-related lung cancer epidemic,
the most common type of cancer observed among smokers
was squamous cell carcinoma, followed by small cell
carcinoma, both of which are more frequent among men.
Although recent studies have reported an association and
dose-response relationship between tobacco smoke and all
histologic types of lung cancer, this association has never-
theless been historically weaker for adenocarcinoma, the
most frequent histology among women. In our study, the
better prognoses for small cell carcinoma in women and
squamous cell carcinoma in men did not appear to be
related to the higher frequency of presentation in one
gender. For both histologic types, the frequency of
presentation in men is more than double that in women.
Moreover, in adenocarcinoma, which is more common
among women, no sex-related differences have been
observed in survival. Hence, the different frequency of
presentation by gender would not seem to explain part of
the difference in survival. Accordingly, neither tobacco
smoke nor gender could be relied upon for an explanation
of differing survival by histologic type.
Although our findings are based on the population
covered by the seven registries, they could nevertheless be
regarded as an approximation of the situation in Spain as
a whole. A number of authors34,35 have considered theimportant point of whether mean survival figures by
geographic region can be taken to represent a wider area.
In our study, Spanish areas with different levels of socio-
economic development were represented.11
The differences observed between the north and south
of the country are due mainly to better prognosis in the
north for squamous cell carcinoma and adenocarcinoma. In
small cell and large cell carcinoma, however, no differ-
ences were observed. One possible explanation would
combine socioeconomic factors, health care, and unfavor-
able disease progression by specific histologic type. Thus, in
the south, a region characterized by a below-average
economic level, provision of less than optimal care might
be leading to poor prognosis in more favorable lung cancer
morphology. Also has to be considered possible differences
in the decision to treat cases with worse prognostic factors.
A study36 carried out in England and Wales showed that
socioeconomic inequalities in lung cancer survival among
men may reflect a higher proportion of patients from the
more deprived socioeconomic groups being more likely to
present comorbidities related to smoking, such as chronic
obstructive pulmonary disease and ischaemic heart disease.
A possible bias in our analysis could be due to the
exclusion of cases known only from death certificates, yet
these account for only 4.4% and 7.4% of cases in men and
Table 5 Relative excess risk of death and 95% confidence interval by histologic type.
Small cell
carcinoma
Large cell
carcinoma
Squamous cell
carcinoma
Adenocarcinoma Other/unspecified
RER 95% CI RER 95% CI RER 95% CI RER 95% CI RER 95% CI
FU
1 year 1 1 1 1 1
2 year 1.13 1.00e1.27 0.61 0.51e0.74 0.68 0.62e0.74 0.53 0.47e0.60 0.42 0.36e0.48
3 year 0.49 0.38e0.63 0.31 0.22e0.45 0.37 0.32e0.42 0.33 0.27e0.40 0.15 0.11e0.21
4 year 0.21 0.13e0.36 0.22 0.13e0.38 0.19 0.15e0.23 0.20 0.16e0.27 0.13 0.09e0.19
5 year 0.19 0.11e0.33 0.15 0.05e0.43 0.14 0.10e0.18 0.17 0.12e0.24 0.12 0.07e0.21
Sex
Female 1 1 1 1 1
Male 1.29 1.02e1.61 0.90 0.72e1.14 0.87 0.73e1.05 1.09 0.98e1.22 1.37 1.18e1.60
Region
North and
North-east
1 1 1 1 1
South 0.93 0.84e1.03 1.06 0.91e1.23 1.19 1.10e1.28 1.18 1.07e1.31 1.15 1.04e1.27
Age group
(years)
15e54 1.00 1.00 1.00 1.00 1.00
55e64 1.17 1.02e1.35 0.92 0.75e1.12 1.03 0.92e1.15 1.05 0.92e1.19 1.58 1.30e1.92
65e99 1.64 1.44e1.87 1.00 0.84e1.19 1.27 1.15e1.41 1.31 1.17e1.46 2.20 1.87e2.58
Deviance/df 0.74 0.73 1.19 0.91 2.19
df 36 31 43 48 37
FU, follow-up duration; RER, relative excess risk of death; 95% CI, 95% confidence interval; and df, degrees of freedom.
Lung cancer prognosis in Spain 1307women, respectively. Another limitation of our study is the
exclusion of patients with zero follow up (7%), that is,
patients with very poor survival (dead at the time of diag-
nosis), patients lost to follow up for different reasons (such
as poorer completeness of follow up) and patients for which
the month and year of the dates of diagnosis and follow up
coincide but for which the day is not available. The
exclusion of zero survival patients does not substantially
affect the results. We have calculated the 5-year relative
survival including the death zero survival patients adding
a day to their follow-up and the ratio female/male for the
5-year relative survival was not affected (1.46 when zero
survival patients were excluded and 1.49 if we include
these patients).
Furthermore, as stage at diagnosis was not routinely
collected by all registries, this information could not be
included in our analysis. However, RS at population level
offers valuable information in the assessment of cancer
care outcome and it is a helpful indicator of progress in
cancer control.
Lastly, owing to the low incidence rates of lung cancer
among women in the period 1995e1999, the low number of
female cases might pose another limitation to our study.
This is the first analysis of lung cancer survival by histologic
type in Spain at population level using data from cancer
registries and standard quality procedures.
In conclusion, lung cancer survival rates in Spain dis-
played better prognosis in women than in men, particularly
among patients with small cell carcinoma or other/
unspecified cancers, and among patients who were under
55 years of age at diagnosis. In order to furnish fullerevidence on differential lung cancer survival among men
and women by histologic group and any possible explana-
tory factors, more comprehensive studies including stage at
diagnosis are called for.Conflict of interest statement
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